Acurx Pharmaceuticals Secures $7.1 Million Through Direct Stock Offering

Acurx Pharmaceuticals Secures Funding for Antibiotic Development

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a forward-thinking biopharmaceutical entity, has shared exciting news regarding its latest financial maneuver aimed at bolstering its efforts in developing innovative antibiotics. On April 16, 2026, the company revealed plans for a registered direct offering that could generate up to $7.1 million with a price set at $3.03 per share. This initiative reflects Acurx's ongoing commitment to addressing the critical need for effective treatments for challenging bacterial infections.

Details of the Offering

Under the agreement, Acurx will sell an aggregate of 825,085 shares, or pre-funded warrants, alongside unregistered short-term warrants which could entitle purchasers to buy up to 1,650,170 shares at an exercise price of $2.78 each. The offering is being facilitated under NASDAQ rules and H.C. Wainwright & Co. will act as the exclusive placement agent for this significant transaction.

The immediate gross proceeds from this offering are projected at approximately $2.5 million, not accounting for the fees owed to the placement agent. Furthermore, should all short-term warrants be exercised, additional funding of about $4.6 million could be realized.

This funding is crucial for Acurx as they strive to enhance their working capital and advance corporate operations, specifically focused on their promising antibiotic candidates aimed at combating urgent medical challenges.

Acurx’s Mission and Product Pipeline

Acurx Pharmaceuticals stands out for its dedication to creating a new class of small molecule antibiotics tailored for tough-to-treat bacterial infections. Their approach hinges on the development of antibiotic candidates featuring a Gram-positive selective spectrum (GPSS®), designed to block the action of bacterial enzyme DNA polymerase IIIC. This mechanism effectively hampers DNA replication, leading to the demise of Gram-positive bacteria.

Currently, one of the crown jewels of Acurx's pipeline is ibezapolstat, which is poised to tackle the damaging Clostridioides difficile infection (CDI). This candidate is ready for Phase 3 international clinical trials, pending necessary funding. Recently, Acurx announced its groundbreaking clinical trial for ibezapolstat in patients dealing with multiply-recurrent CDI (rCDI). This trial marks a potential paradigm shift in treating rCDI by streamlining the process from two agents to a singular, effective treatment.

The company’s roadmap involves an open-label pilot trial designed to gain pivotal experience with ibezapolstat among patients suffering from multiple occurrences of CDI. The insights gathered will shape a comprehensive Phase 3 trial aimed at securing FDA approval through the Limited Population Pathway for Antibacterial and Antifungal Drugs.

Beyond ibezapolstat, Acurx is also advancing the development of another promising oral product candidate curated for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and plans are in motion for a treatment protocol dedicated to inhaled anthrax.

Looking Ahead

Acurx Pharmaceuticals is aligned with a vision to revolutionize the antibiotic landscape and effectively address antibiotic resistance, a growing global epidemic. With this recent financial injection and robust pipeline, the company is poised to make significant strides in the biopharmaceutical arena.

For more detailed information on Acurx and its innovative treatment candidates, please visit www.acurxpharma.com.

Note

Forward-looking statements are prevalent in this announcement, highlighting potential market fluctuations and the various risks that might affect the company’s future performance. Acurx advises stakeholders to consider these potential risks as they proceed.